Gastrointestinal Oncology
Enterome’s clinical research includes metastatic colorectal carcinoma, with attention to patients who have unresectable and previously treated disease. The work centers on cancer immunotherapy approaches in a heavily pretreated solid tumor setting.
- Colorectal carcinoma
- Metastatic solid tumors
- Immune-based cancer treatment
The sponsor’s activity in this area reflects interest in treatment-resistant gastrointestinal malignancies and combinations involving immune checkpoint inhibition and anti-angiogenic therapy.
Indolent B-cell Lymphomas
The company also studies indolent non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma. This program focuses on hematologic malignancies with a slow-growing but persistent clinical course.
- Follicular lymphoma
- Marginal zone lymphoma
- Indolent non-Hodgkin’s lymphoma
Research in this field is directed toward B-cell lymphoma biology and immune-targeted treatment strategies.
Cancer Vaccines
Enterome’s pipeline includes novel cancer vaccine therapy aimed at both hematologic and solid tumor indications. The sponsor’s clinical activity highlights interest in tumor-directed immune priming and vaccine-based oncology treatment.
- Cancer vaccine therapy
- Tumor immunology
- Immune activation
This area links vaccine development with broader oncology programs involving combination strategies and disease-specific immune response assessment.
Combination Immunotherapy
Clinical studies funded by the sponsor explore combinations with nivolumab, bevacizumab, lenalidomide, and rituximab, placing emphasis on coordinated immuno-oncology and targeted therapy approaches.
- Immune checkpoint blockade
- Monoclonal antibody-based treatment
- Combination oncology regimens
The therapeutic scope spans both solid tumors and lymphoid cancers, with clinical interest in integrating immune and biologic agents.
